Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced it has entered into a definitive agreement with Pharmaceutical Strategies Group (PSG) to acquire its 340B Link business for total aggregate cash consideration of $225 million, subject to customary adjustments. The acquisition will add a comprehensive and differentiated suite of software-enabled services and solutions used by certain eligible hospitals, health systems, clinics, and entities to manage compliance and capture 340B drug cost savings on outpatient prescriptions filled through the eligible entityÕs pharmacy or a contracted pharmacy partner.
Read the full article: Omnicell to Acquire Pharmaceutical Strategy Group’s Leading 340B Software-Enabled Service Business //
Source: https://www.businesswire.com/news/home/20200812005397/en/Omnicell-Acquire-Pharmaceutical-Strategy-Group%E2%80%99s-Leading-340B